Fabrication of lipospheres for paclitaxel and assessment of in vitro cytotoxicity against U373 cancer cell lines

Thai Journal of Pharmaceutical Sciences

Volumn 36, Issue 3, 2012, Pages 117-130

  Nerkar, Nilakshi ^a   Bajaj, Amrita ^b   Shrikhande, Shruti ^a   Jain, Darshana ^a  

^a SNDT WOMEN S UNIVERSITY   (India)

^b Narsee Monjee Institute of Management Studies   (India)

Author keywords

Cytotoxicity; Lipospheres; Paclitaxel

Indexed keywords

ACETIC ACID ETHYL ESTER; DICHLOROMETHANE; DIETHYLENE GLYCOL MONOETHYL ETHER; DOXORUBICIN; DRUG CARRIER; GLYCEROL BEHENATE; GLYCEROL STEARATE; LIPOSPHERE; PACLITAXEL; POLOXAMER; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIODEGRADABILITY; CANCER CELL CULTURE; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG CYTOTOXICITY; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG RELEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; INFRARED SPECTROSCOPY; PARTICLE SIZE; PHYSICAL CHEMISTRY; SCANNING ELECTRON MICROSCOPY; SURFACE PROPERTY; THERMODYNAMICS; X RAY DIFFRACTION;

EID: 84872546699     PISSN: 01254685     EISSN: 19054637     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. D. Kohler, and B.R. Goldspiel. Paclitaxel (Taxol), Pharmaceutical and pharmacological issues, Eur. Hosp. Pharm. 1: 37-141 (1995).
2. A.K. Singla, A. Garg, and D. Aggarwal. Paclitaxel and its formulations, Int. J. Pharm. 235: 179-192 (2002).
3. D. Friedland, G. Gorman, and J. Treat. Hypersenstivity reactions from taxol and etoposide, J. Natl. Cancer Inst. 85: 2036 (1993).
4. R.B. Weiss, R.C. Donehower, P.H. Wiernik, T. Ohnuma, R.J. Gralla, D.L. Trump, J.R. Baker., D.A. Van Echo, D.D. VonHoff, and B. Leyland-Jones. Hypersenstivity reactions with taxol, J. Clin. Oncol. 8: 1263 (1990).
5. M. Allwood, and H. Martin. The extraction of diethylhexylphthalate (DEHP) from polyvinyl chloride components of intravenous infusion containers and administration sets by paclitaxel injection, Int. J. Pharm. 127: 65-71 (1996).
6. M.L. Fjallskog, L. Frii, and J. Bergh. Is Cremophor, solvent for paclitaxel, cytotoxic? Lancet. 342: 876-879 (1993).
7. R.H. Muller, K.S. Mader, and S. Gohla. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art, Eur. J. Pharm. Biopharm. 50: 161-177 (2000).
8. M. Takenaga. Application of lipid microspheres for the treatment of cancer, Adv. Drug Del. Rev. 20: 209-219 (1996).
9. R. Cortesi, E. Esposito, G. Luca, and G. Nastruzzi. Production of lipospheres as carriers for bioactive compounds, Biomaterials. 23: 2283-2294 (2002).
10. K. Inoue, Y. Aoki, M. Hayashi, S. Kitahara, H. Tanabe, M. Kiyoki, and H. Araki. Ex vivo anti-platelet effects of isocarbacyclin methyl ester incorporated in lipid microspheres in rabbits, Drug Res. 45: 980-984 (1995).
11. M. Nasr, S. Mansour, N. Mortada, and A.A. Shamy. Lipospheres as carriers for topical delivery of aceclofenac: preparation, characterization and in vivo evaluation, AAPS Pharm Sci Tech, 9: 154-162 (2008).
12. S. Toongsuwan, L. Li, B.K. Erickson, and H. Chang. Formulation and characterization of bupivacaine lipospheres, Int. J. Pharm. 280: 57-65 (2004).
13. D.B. Masters, and A.J. Domb. Lipospheres local anesthetic termed release for perineural site application, Pharm. Res. 15: 1038-1045 (1998).
14. D. Hou, C. Xie, K. Huang, and C. Zhu. The production and characteristics of solid lipid nanoparticles (SLNs), Biomaterials. 24: 1781-1785 (2003).
15. N. S. Barakat, and A.E.B. Yassin. In vitro characterization ofcarbamazepine-loaded precifac lipospheres, Drug Deliv. 13: 95-104 (2006).